|
drug
|
route of administration
|
dosage (Dosages given in the table may differ from those recommended
by the manufacturers.
Insufficient data are available on which to base specific recommendations
for the use of one loading regimen over another for patients with ischemic
heart disease or impaired left ventricular function, and these drugs should
be used cautiously or not at all in such patients)
|
potential adverse effects
|
| amiodarone |
oral |
inpatient: 1.2–1.8 g per day in divided dose until 10 g total, then
200–400 mg per day maintenance or 30 mg/kg as single dose |
hypotension, bradycardia, QT prolongation, torsade de pointes
(rare), GI upset, constipation, phlebitis (IV) |
| outpatient: 600–800 mg per day divided dose until 10 g total, then
200–400 mg per day maintenance |
| intravenous/oral |
5–7 mg/kg over 30–60 min, then 1.2–1.8 g per day continuous IV or in
divided oral doses until 10 g total, then 200–400 mg per day maintenance |
| dofetilide |
oral |
creatinine clearance (mL/min) => Dose (mcg BID)
-
> 60 => 500
-
40-60 => 250
-
20-40 => 125
-
< 20 => contraindicated
|
QT prolongation, torsade de pointes; adjust dose for renal function,
body size, and age |
| flecainide (insufficient data are available on which to
base specific recommendations for the use of one loading regimen over another
for patients with ischemic heart disease or impaired left ventricular function,
and these drugs should be used cautiously or not at all in such patients) |
oral |
200–300 mg |
hypotension, rapidly conducting atrial flutter |
| intravenous |
1.5–3.0 mg per kg over 10–20 min |
| ibutilide |
intravenous |
1 mg over 10 min; repeat 1 mg when necessary |
QT prolongation, torsade de pointes |
| propafenone |
oral |
450–600 mg |
| intravenous |
1.5–2.0 mg per kg over 10–20 min |
| quinidine (the use of quinidine loading to achieve pharmacological
conversion of atrial fibrillation is controversial, and safer methods are
available with the alternative agents listed in the table. Quinidine should
be used with caution) |
oral |
0.75–1.5 g in divided doses over 6–12 h, usually with a rate-slowing
drug |
QT prolongation, torsade de pointes, GI upset, hypotension |
Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent
paroxysmal or persistent atrial fibrillation. Drugs are listed alphabetically
and not in order of suggested use.
|
drug (listed alphabetically)
|
daily dosage
|
potential adverse effect
|
| amiodarone |
100–400 mg |
photosensitivity, pulmonary toxicity, polyneuropathy, GI upset, bradycardia,
torsade de pointes (rare), hepatic toxicity, thyroid dysfunction |
| disopyramide |
400–750 mg |
torsade de pointes, HF, glaucoma, urinary retention, dry mouth |
| dofetilide |
500–1000 mg (a loading dose of 600 mg per
day is usually given for one month or 1000 mg per day over 1 week) |
torsade de pointes |
| flecainide |
200–300 mg |
ventricular tachycardia, congestive HF, enhanced AV nodal conduction
(conversion to atrial flutter) |
| procainamide |
1000–4000 mg |
torsade de pointes, lupus-like syndrome, GI symptoms |
| propafenone |
450–900 mg |
ventricular tachycardia, congestive HF, enhanced AV nodal conduction
(conversion to atrial flutter) |
| quinidine |
600–1500 mg |
torsade de pointes, GI upset, enhanced AV nodal conduction |
| sotalol |
240–320 mg (dose should be adjusted for renal function and QT-interval
response during in-hospital initiation phase) |
torsade de pointes, congestive HF, bradycardia, exacerbation of chronic
obstructive or bronchospastic lung disease |
Recommendations for use of orally administered pharmacological agents for
heart rate control in patients with atrial fibrillation :
|
drug (listed alphabetically within each class of recommendation)
|
loading dose
|
onset
|
usual maintenance dose (the usual ones necessary, but higher doses
may be appropriate in some patients)
|
major side effects
|
recommendation
|
| digoxin |
0.25 mg PO each 2 h; up to 1.5 mg |
2 h |
0.125–0.375 mg daily |
Digitalis toxicity, heart block, bradycardia |
I |
diltiazem |
NA |
2-4 h |
120–360 mg daily in divided doses; slow release available |
hypotension, heart block, HF |
I |
| metoprolol (the table includes representative members of the type of
beta-blocker drugs, but other, similar agents could be used for this indication
in appropriate doses.) |
NA |
4-6 h |
25–100 mg BID |
hypotension, heart block, bradycardia, asthma, HF |
I |
| propanolol |
NA |
60-90 min |
80–240 mg daily in divided doses |
hypotension, heart block, bradycardia, asthma, HF |
I |
| verapamil |
NA |
1-2 h |
120–360 mg daily in divided doses; slow release available |
hypotension, heart block, HF, digoxin interaction |
I |
| amiodarone |
800 mg daily for 1 wk 600 mg daily for 1 wk 400 mg daily for 4–6 wk |
1-3 wk |
200 mg daily |
pulmonary toxicity, skin discoloration, hypothyroidism, corneal deposits,
optic neuropathy, warfarin interaction, proarrhythmia |
Ib |
Intravenous pharmacological agents for heart rate control in patients with
atrial fibrillation :
|
drug
|
loading dose
|
onset
|
maintenance dose
|
major side effects
|
class recommendation
|
diltiazem |
0.25 mg/kg IV over 2 min |
2-7 mm |
5-15 mg per hour infusion |
hypotension, heart block, HF |
I (type IIb in congestive HF) |
| esmolol (only representative members of the type of b-adrenergic
antagonist drugs are included in the table, but other, similar agents could
be used for this indication in appropriate doses) |
0.5 mg/kg over 1 min |
5 min |
0.05–0.2 mg·kg-1·min-1 |
hypotension, heart block, bradycardia, asthma, HF |
I |
| metoprolol |
2.5–5 mg IV bolus over 2 min; up to 3 doses |
5 min |
NA |
hypotension, heart block, bradycardia, asthma, HF |
I (type IIb in congestive HF) |
| propanolol |
0.15 mg/kg IV |
5 min |
NA |
hypotension, heart block, bradycardia, asthma, HF |
I (type IIb in congestive HF) |
| verapamil |
0.075–0.15 mg/kg IV over 2 min |
3-5 min |
NA |
hypotension, heart block, HF |
I (type IIb in congestive HF) |
| digoxin |
0.25 mg IV each 2 h, up to 1.5 mg |
2 hr |
0.125–0.25 mg daily |
Digitalis toxicity, heart block, bradycardia |
IIb (type I in congestive HF) |
Recommendations for pharmacological cardioversion of AF <= 7 days duration
(the doses of medications used in these studies may not be the same as
those recommended by the manufacturers) :